...
regn-img

Regeneron Pharmaceuticals Inc, Common Stock

REGN

NSQ

$731.3

-$9.67

(-1.31%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$84.94B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
19.1195
Volume info-icon
This is the total number of shares traded during the most recent trading day.
684.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.14
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$735.95 L
$1211.2 H
$731.3

About Regeneron Pharmaceuticals Inc, Common Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameREGNSectorS&P500
1-Week Return-6%-2.27%-0.57%
1-Month Return-9.08%-3.96%1.21%
3-Month Return-36.59%-9.7%7.57%
6-Month Return-28.76%-3.37%11.45%
1-Year Return-16.53%3.71%28.48%
3-Year Return10.78%3.8%29.52%
5-Year Return94.28%39.78%90.66%
10-Year Return82.36%106.91%203.75%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue7.86B8.50B16.07B12.17B13.12B[{"date":"2019-12-31","value":48.93,"profit":true},{"date":"2020-12-31","value":52.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.74,"profit":true},{"date":"2023-12-31","value":81.62,"profit":true}]
Cost of Revenue782.20M1.12B2.44B1.56B883.70M[{"date":"2019-12-31","value":32.09,"profit":true},{"date":"2020-12-31","value":45.94,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":64.02,"profit":true},{"date":"2023-12-31","value":36.25,"profit":true}]
Gross Profit7.08B7.38B13.63B10.61B12.23B[{"date":"2019-12-31","value":51.94,"profit":true},{"date":"2020-12-31","value":54.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.84,"profit":true},{"date":"2023-12-31","value":89.73,"profit":true}]
Gross Margin90.05%86.82%84.83%87.18%93.26%[{"date":"2019-12-31","value":96.56,"profit":true},{"date":"2020-12-31","value":93.09,"profit":true},{"date":"2021-12-31","value":90.96,"profit":true},{"date":"2022-12-31","value":93.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses4.87B3.80B4.69B5.62B7.07B[{"date":"2019-12-31","value":68.9,"profit":true},{"date":"2020-12-31","value":53.75,"profit":true},{"date":"2021-12-31","value":66.3,"profit":true},{"date":"2022-12-31","value":79.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income2.21B3.58B8.95B4.74B4.05B[{"date":"2019-12-31","value":24.7,"profit":true},{"date":"2020-12-31","value":39.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":52.97,"profit":true},{"date":"2023-12-31","value":45.24,"profit":true}]
Total Non-Operating Income/Expense189.10M176.90M321.70M220.60M497.80M[{"date":"2019-12-31","value":37.99,"profit":true},{"date":"2020-12-31","value":35.54,"profit":true},{"date":"2021-12-31","value":64.62,"profit":true},{"date":"2022-12-31","value":44.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income2.43B3.81B9.33B4.86B4.20B[{"date":"2019-12-31","value":26.05,"profit":true},{"date":"2020-12-31","value":40.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":52.1,"profit":true},{"date":"2023-12-31","value":45.03,"profit":true}]
Income Taxes313.30M297.20M1.25B520.40M245.70M[{"date":"2019-12-31","value":25.05,"profit":true},{"date":"2020-12-31","value":23.77,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":41.62,"profit":true},{"date":"2023-12-31","value":19.65,"profit":true}]
Income After Taxes2.12B3.51B8.08B4.34B3.95B[{"date":"2019-12-31","value":26.2,"profit":true},{"date":"2020-12-31","value":43.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":48.96,"profit":true}]
Income From Continuous Operations2.12B3.51B8.08B4.34B3.99B[{"date":"2019-12-31","value":26.2,"profit":true},{"date":"2020-12-31","value":43.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":49.42,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income2.12B3.51B8.08B4.34B3.95B[{"date":"2019-12-31","value":26.2,"profit":true},{"date":"2020-12-31","value":43.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.72,"profit":true},{"date":"2023-12-31","value":48.96,"profit":true}]
EPS (Diluted)24.6431.6571.3842.4043.78[{"date":"2019-12-31","value":34.52,"profit":true},{"date":"2020-12-31","value":44.34,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.4,"profit":true},{"date":"2023-12-31","value":61.33,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

REGN
Cash Ratio 2.68
Current Ratio 5.28
Quick Ratio 4.46

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

REGN
ROA (LTM) 7.41%
ROE (LTM) 17.17%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

REGN
Debt Ratio Lower is generally better. Negative is bad. 0.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.78

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

REGN
Trailing PE 19.12
Forward PE 17.15
P/S (TTM) 6.13
P/B 2.90
Price/FCF 77
EV/R 5.62
EV/Ebitda 14.15
PEG 1.15

FAQs

What is Regeneron Pharmaceuticals Inc share price today?

Regeneron Pharmaceuticals Inc (REGN) share price today is $731.3

Can Indians buy Regeneron Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Regeneron Pharmaceuticals Inc (REGN) on Vested. To buy Regeneron Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in REGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Regeneron Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Regeneron Pharmaceuticals Inc (REGN) via the Vested app. You can start investing in Regeneron Pharmaceuticals Inc (REGN) with a minimum investment of $1.

How to invest in Regeneron Pharmaceuticals Inc shares from India?

You can invest in shares of Regeneron Pharmaceuticals Inc (REGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in REGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Regeneron Pharmaceuticals Inc shares
What is Regeneron Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Regeneron Pharmaceuticals Inc (REGN) is $1211.2. The 52-week low price of Regeneron Pharmaceuticals Inc (REGN) is $735.95.

What is Regeneron Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Regeneron Pharmaceuticals Inc (REGN) is 19.1195

What is Regeneron Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Regeneron Pharmaceuticals Inc (REGN) is 2.90

What is Regeneron Pharmaceuticals Inc dividend yield?

The dividend yield of Regeneron Pharmaceuticals Inc (REGN) is 0.00%

What is the Market Cap of Regeneron Pharmaceuticals Inc?

The market capitalization of Regeneron Pharmaceuticals Inc (REGN) is $84.94B

What is Regeneron Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Regeneron Pharmaceuticals Inc is REGN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top